Royalty Pharma (RPRX)

• Market cap: $14.5B
• 1 day: 0.27%
• 5 days: 2.96%
• 1 month: 10.30%
• 3 months: 26.59%
• 6 months: 21.09%
• Year to date: 29.59%
• 1 year: 7.01%
• 5 years: -24.90%
• 10 years: -24.90%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Employees: 99

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

466% more call options, than puts

Call options by funds: $18.1M | Put options by funds: $3.2M

37% more first-time investments, than exits

New positions opened: 67 | Existing positions closed: 49

10% more repeat investments, than reductions

Existing positions increased: 151 | Existing positions reduced: 137

2.94% more ownership

Funds ownership: 68.91% [Q3] → 71.85% (+2.94%) [Q4]

2% more funds holding

Funds holding: 388 [Q3] → 396 (+8) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 9 [Q3] → 9 (+0) [Q4]

7% less capital invested

Capital invested by funds: $8.74B [Q3] → $8.14B (-$595M) [Q4]